Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status

BACKGROUND: Patients with non–small cell lung cancer (NSCLC) and a poor Eastern Cooperative Oncology Group Performance Status (ECOG PS) have been excluded from phase III immunotherapy clinical trials. We sought to evaluate clinical outcomes to first-line pembrolizumab in patients with advanced NSCLC...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Immunother Cancer
Autori principali: Alessi, Joao V, Ricciuti, Biagio, Jiménez-Aguilar, Elizabeth, Hong, Fangxin, Wei, Zihan, Nishino, Mizuki, Plodkowski, Andrew J, Sawan, Peter, Luo, Jia, Rizvi, Hira, Carter, Brett W, Heymach, John V, Altan, Mehmet, Hellmann, Matthew, Awad, Mark
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Publishing Group 2020
Soggetti:
Clinical/Translational Cancer Immunotherapy
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7406027/
https://ncbi.nlm.nih.gov/pubmed/32753547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001007
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi